MX2016014768A - Dosificacion de dasotralina y metodo para el tratamiento del trastorno por deficit de atencion con hiperactividad adhd. - Google Patents
Dosificacion de dasotralina y metodo para el tratamiento del trastorno por deficit de atencion con hiperactividad adhd.Info
- Publication number
- MX2016014768A MX2016014768A MX2016014768A MX2016014768A MX2016014768A MX 2016014768 A MX2016014768 A MX 2016014768A MX 2016014768 A MX2016014768 A MX 2016014768A MX 2016014768 A MX2016014768 A MX 2016014768A MX 2016014768 A MX2016014768 A MX 2016014768A
- Authority
- MX
- Mexico
- Prior art keywords
- dasotraline
- adhd
- treatment
- dosage
- exhibit
- Prior art date
Links
- SRPXSILJHWNFMK-MEDUHNTESA-N dasotraline Chemical compound C1([C@@H]2CC[C@H](C3=CC=CC=C32)N)=CC=C(Cl)C(Cl)=C1 SRPXSILJHWNFMK-MEDUHNTESA-N 0.000 title abstract 2
- 229950006987 dasotraline Drugs 0.000 title abstract 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000011269 treatment regimen Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se describen formas de dosificación y regímenes de tratamiento que emplean dasotralina para tratar el trastorno de hiperactividad con déficit de atención (ADHD). Las composiciones descritas en la presente exhiben potencial de abuso.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461992619P | 2014-05-13 | 2014-05-13 | |
PCT/US2015/030357 WO2015175523A1 (en) | 2014-05-13 | 2015-05-12 | Dosage of dasotraline and method for treatment of adhd |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016014768A true MX2016014768A (es) | 2017-03-06 |
Family
ID=54480549
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016014768A MX2016014768A (es) | 2014-05-13 | 2015-05-12 | Dosificacion de dasotralina y metodo para el tratamiento del trastorno por deficit de atencion con hiperactividad adhd. |
Country Status (10)
Country | Link |
---|---|
US (1) | US10076503B2 (es) |
EP (1) | EP3143000A4 (es) |
JP (1) | JP2017515849A (es) |
KR (1) | KR20170005088A (es) |
CN (1) | CN106660937A (es) |
AU (1) | AU2015259346A1 (es) |
CA (1) | CA2948839A1 (es) |
IL (1) | IL248847A0 (es) |
MX (1) | MX2016014768A (es) |
WO (1) | WO2015175523A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210386689A1 (en) * | 2018-10-31 | 2021-12-16 | Sunovion Pharmaceuticals Inc. | Methods of treating central nervous system disorders |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4556676A (en) * | 1979-11-01 | 1985-12-03 | Pfizer Inc. | Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
US4981870A (en) * | 1989-03-07 | 1991-01-01 | Pfizer Inc. | Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants |
KR101067045B1 (ko) * | 2002-09-16 | 2011-09-22 | 선오비온 파마슈티컬스 인코포레이티드 | 트랜스 4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로-1-나프탈렌아민을 사용한 cns 장애의 치료 |
DK2506842T3 (en) * | 2009-12-04 | 2015-02-23 | Sunovion Pharmaceuticals Inc | Formulations, salts and polymorphs of transnorsertraline and their applications |
-
2015
- 2015-05-12 MX MX2016014768A patent/MX2016014768A/es unknown
- 2015-05-12 AU AU2015259346A patent/AU2015259346A1/en not_active Abandoned
- 2015-05-12 WO PCT/US2015/030357 patent/WO2015175523A1/en active Application Filing
- 2015-05-12 KR KR1020167034705A patent/KR20170005088A/ko unknown
- 2015-05-12 US US15/310,351 patent/US10076503B2/en active Active
- 2015-05-12 CA CA2948839A patent/CA2948839A1/en not_active Abandoned
- 2015-05-12 CN CN201580027353.3A patent/CN106660937A/zh active Pending
- 2015-05-12 JP JP2016567529A patent/JP2017515849A/ja active Pending
- 2015-05-12 EP EP15792455.6A patent/EP3143000A4/en not_active Withdrawn
-
2016
- 2016-11-09 IL IL248847A patent/IL248847A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL248847A0 (en) | 2017-01-31 |
US10076503B2 (en) | 2018-09-18 |
CN106660937A (zh) | 2017-05-10 |
CA2948839A1 (en) | 2015-11-19 |
EP3143000A1 (en) | 2017-03-22 |
AU2015259346A1 (en) | 2016-12-08 |
KR20170005088A (ko) | 2017-01-11 |
WO2015175523A1 (en) | 2015-11-19 |
US20170266134A1 (en) | 2017-09-21 |
EP3143000A4 (en) | 2017-12-13 |
JP2017515849A (ja) | 2017-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019007030A (es) | Composiciones y metodos para el tratamiento del cancer. | |
EA201891200A1 (ru) | Композиции, содержащие бактериальные штаммы | |
IL253979A0 (en) | Methods, preparations and kits for cancer treatment | |
GB2541571A (en) | Pharmaceutical compositions | |
NZ731467A (en) | Anti-tim3 antibodies and methods of use | |
MX2017011997A (es) | Carbamatos de piperacina y metodos de preparacion y uso. | |
MY192927A (en) | Fused bicyclic compounds for the treatment of disease | |
SI3153169T1 (sl) | Metoda za zdravljenje tumorja, farmacevtska sestava in komplet škatlic z zdravili | |
MX369623B (es) | Compuestos biciclicos fusionados para el tratamiento de enfermedades. | |
HK1244429A1 (zh) | 特別用於治療注意力缺陷障礙的方法和組合物 | |
MX2018000715A (es) | Metodos para tratar cancer usando apilimod. | |
MX2019013808A (es) | Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer. | |
EP3252019A4 (en) | Method for treating wastewater, and activator for treating wastewater | |
EP3187579A4 (en) | Composition, support, wastewater treatment system, wastewater treating method, deodorization method, and batch wastewater treating method | |
PH12017501864A1 (en) | Compositions and methods for treating autism | |
MX2017006026A (es) | Apilimod para uso en el tratamiento de cancer colorrectal. | |
MX2017016114A (es) | Metodos para tratar o prevenir una proteopatia. | |
EA201790156A1 (ru) | Азетидинилоксифенилпирролидиновые соединения | |
MX2017012553A (es) | Compuestos espirociclicos. | |
PH12017500602A1 (en) | Methods for treating ocular conditions | |
MX2016009537A (es) | Metodo para tratar ropa. | |
MX2016009655A (es) | Metodos novedosos para el tratamiento del cancer. | |
PH12016501838A1 (en) | Compounds and their methods of use | |
JO3541B1 (ar) | علاجات طبية قائمة على اناموريلين | |
MX2019003755A (es) | Regimen de dosificacion de avelumab para el tratamiento de cancer. |